Investment Research & Advisory Group’s Protalix BioTherapeutics PLX Stock Holding History

Investment Research & Advisory Group’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.33K	Hold	1,000	–	–	﹤0.01%	280
2026 Q1	$2.17K	Hold	1,000	–	–	﹤0.01%	239
2025 Q4	$1.8K	Hold	1,000	–	–	﹤0.01%	236
2025 Q3	$2.22K	Hold	1,000	–	–	﹤0.01%	219
2025 Q2	$1.48K	Buy	1,000 +400	+67%	+$818	﹤0.01%	217
2025 Q1	$1.54K	Buy	+600	New	+$1.43K	﹤0.01%	223

Other funds holding PLX

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

HIM

Harbour Investment Management Edmonds, Washington $194M AUM 15.93% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

OGF

Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Investment Research & Advisory Group's PLX Position: Q2 2026 in Review

Investment Research & Advisory Group held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 1,000 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #280.

Investment Research & Advisory Group first reported a position in PLX in Q1 2025 and has held it in 6 quarters since. 18 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Investment Research & Advisory Group held 1,000 shares of Protalix BioTherapeutics worth $2.33K as of Q2 2026.
Investment Research & Advisory Group left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Investment Research & Advisory Group's portfolio in Q2 2026, its #280 holding.
Investment Research & Advisory Group first reported a position in Protalix BioTherapeutics in Q1 2025 and has held it in 6 quarters since.
18 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Investment Research & Advisory Group's 13F filing for Q2 2026, filed 23 Jul 2026.